Solid Biosciences LLC is a biotechnology business based in the US. Solid Biosciences LLC shares (SLDB) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $5.41 – an increase of 11.55% over the previous week. Solid Biosciences LLC employs 88 staff and has a market cap (total outstanding shares value) of 0.00.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $5.41 |
|---|---|
| 52-week range | $2.63 - $15.05 |
| 50-day moving average | $6.32 |
| 200-day moving average | $8.45 |
| Wall St. target price | $17.43 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-3.04 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $5.41 from 2024-11-22
| 1 week (2024-11-15) | 11.55% |
|---|---|
| 1 month (2024-10-24) | -3.22% |
| 3 months (2024-08-23) | -43.41% |
| 6 months (2024-05-23) | -30.73% |
| 1 year (2023-11-22) | 106.49% |
|---|---|
| 2 years (2022-11-23) | -19.61% |
| 3 years (2021-11-23) | 29.55 |
| 5 years (2019-11-22) | 64.5 |
| Gross profit TTM | $13.6 million |
|---|---|
| Return on assets TTM | -35.33% |
| Return on equity TTM | -65.79% |
| Profit margin | 0% |
| Book value | $4.29 |
| Market Capitalization | $216.2 million |
TTM: trailing 12 months
We're not expecting Solid Biosciences LLC to pay a dividend over the next 12 months.
Solid Biosciences LLC's shares were split on a 1:15 basis on 27 October 2022 . So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Solid Biosciences LLC shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Solid Biosciences LLC shares which in turn could have impacted Solid Biosciences LLC's share price.
Over the last 12 months, Solid Biosciences LLC's shares have ranged in value from as little as $2.6301 up to $15.05. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Solid Biosciences LLC's is 1.928. This would suggest that Solid Biosciences LLC's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Solid Biosciences Inc. , a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
The best platforms to use for automatic investing include Wealthfront, SoFi, Schwab, Vanguard, Titan, Acorns and more. See our full list here.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
5 Betterment robo-advisor alternatives to consider when building your portfolio.
What you need to know about investing in the leading indicator for the overall US stock market.
How do you gift stocks to loved ones? Learn the ins and outs of finding the right investments for them.
Check out the best-performing ETFs so far in 2024.
Acorns is a financial service that rounds up your purchases and turns the extra change into investments.